Dr. Zhang: The age of genes has come.

Introduction: Genes are the source of all life phenomena, which determine the functioning of every cell and organism!----genes are the source of all life phenomena, determining the functioning of every cell and organisminterpretation of gene code has always been the ultimate dream of mankind, and also promote the rapid development of gene sequencing technology, gene sequencing is increasingly being applied to human health as the cost of sequencing a human genome has fallen from $3 billion in 2001 to $1,000As DrZhang Patriot, founder and CEO of DiaCarta, said in an interview with Biodiscovery, the age of genes has arrived01 introduced in China, landing in Nanjing in recent years, through molecular diagnosis to guide patients personalized precision treatment has gradually become the consensus of cancer cliniciansagainst this background, liquid biopsies quickly become the focus of clinical attentionas a branch of in vitro diagnosis, liquid biopsies are diagnosed by blood or urine and other diseases such as cancer, the advantage of which is that the risk of biopsy is effectively reduced by non-invasive samplingDiaCarta (Dikie Bio) is the world's leading molecular diagnostic reagents, technology platform research and development company, headquartered in San Francisco, USA, with the world's leading liquid biopsy molecular diagnostic technology, and the world's first QClamp™ XNA molecular embedding technology and nanotechnology combined with the use of liquid biopsythis innovation is superior to second-generation sequencing technology in terms of time, cost and sensitivity for clinical detection of ctDNADrZhang has always wanted to take advantage of DiaCarta's years of accumulation abroad, bring home some good independent research and development technology, break down the technical barriers in early screening of cancer in China, so as to meet clinical needs and benefit the general publicafter many visits, in 2016, The Diki Bio officially signed a contract to settle in Nanjing Biopharmaceutical ValleyNovember 20, 2017, DiaCarta (Diki Bio) announced the completion of a new round of financing amounting to 300 million yuan to support global market development, major project strategic cooperation, new product development, FDA and CFDA filingswith its leading technology in the field of molecular diagnostics and genetic testing, DiaCarta (Diki Bio) has also successfully entered the Yangzi Co-center, the world's largest high-throughput sequencing platform and the largest national data center under the Yangzi Guotou Group Asked why the site was located in Nanjing, Dr Zhang explained, "DiaCarta," as a company with mature and well-funded products, needs the park to support software such as qualification approval and we have the honor to co-create China's first national health care data center with Yangzi Co-center, which has far-reaching implications for the company's development " 02 Breakthrough Technology to Address Bottlenecks In June 2018, the "25 Top Life Technologies of 2018" competition, sponsored by THE JOURNAL OF CICIO Applications, was concluded, with DiaCarta (Dekybio) successfully selected for its strengths in personalized diagnostics, translational medicine genomics, the United States and China in clinical sample testing services mentioned this honor, Dr Zhang said modestly, can be named "2018 25 top life technology" is also the market for our technology precipitation recognition "We have several technical platforms, including QClamp ™ XNA molecular embedding technology, which is an international initiative that solves a bottleneck in liquid biopsy," he added "specifically, the technique uses Watson-Crick base pairing hybridization to obtain targeted DNA sequences based on its proprietary XNA-based NGS library preparation technology, DiaCarta scientists selectively amplify low-frequency mutations and block polymerase amplification of "normal" (wild) DNA this allows us to perform minimal NGS testing to find these low-frequency mutations and generate results within 48 hours use standard analysis processes to quickly analyze data without extensive bioinformatics to handle the noise of wild-type results, which increases the reliability of detecting low-frequency mutations in tumors Dr Zhang's image, "like a pile of grass in a needle." the bottleneck facing liquid biopsies now is that, whether it's a generation, two or three generation sequencing, we're going to extract DNA first, we're going to expand the DNA in PCR, and we're going to have more and more of adhesion of non-mutant DNA (i.e., 'grass') we break the rules and develop QClamp ™ XNA molecular chime technology through reverse thinking, filtering out this 'grass' in the amplification process, only amplification of this 'needle' this technology is conducive to the rapid and accurate detection of problematic mutant DNA, the solution of the gene detection of non-mutant DNA interference bottleneck, greatly improve the sensitivity and specificity of genetic detection "Because QClamp ™ XNA's breakthrough in molecular chimeric technology, it can really solve clinical problems and bring DiaCarta (Diki biology) to the attention of domestic and international institutions." dr Zhang was impressed by a professor at the Einstein College of Medicine in New York who treated patients with clinical pinhole punctures such as pneumonia or thyroid cancer, the amount of cells punctured in the pinhole is very small, if detected in the traditional way, the amount of DNA is not enough, and easy to cause pollution later successfully addressed the bottleneck through DiaCarta's technology, and published an article in 2017 there are many cases , such as Professor Zheng Shu, former president of Zhejiang University, and Professor Lu Wei of Shanghai Chest Hospital "We're pleased that our technology is really solving clinical problems, " , " Dr Zhang said 03 find the core, continuous innovation Today, gene sequencing has become not only a common technology in life science research, but also gradually applied to the field of human health, profoundly changing the existing clinical diagnosis, drug research and development and medical health model the past few years, precision medicine has attracted a lot of capital investment, new start-ups are springing up two years of light gene sequencing services companies have appeared hundreds, and then continue to be eliminated by the market "It also serves as a wake-up call for entrepreneurs to keep their businesses running without core technologies and core products, " dr Zhang mused shortcut overbender doesnot apply to every industry businesses need to go back to the point to find their core and make their own speciality " innovation is the first driving force to lead the development of enterprises, but also the concept that the deky creatures have been adhered to since its inception Dr Zhang's eyes firmly said, "Our research and development team invests a lot of manpower and material resources in this field, in ensuring technological innovation, but also actively cooperate with clinical experts to truly solve clinical problems." "Currently, DiaCarta's diagnostic kits and cancer genetic testing products cover cancer-driven genetic quantitative testing, early screening for colorectal cancer, cancer targeted genome second-generation sequencing, lung cancer monitoring fluid biopsy, tumor molecular marker quantitative testing, and a range of testing products around immunotherapy (such as CAR-T) and cell therapy." also has a precision medical big data management platform that provides world-class genetic data collection, management, analysis and mining services 04 deep work, pratt and wide spread the mass with the development of large-scale biological sample database, histology, big data, precision medicine has been significantly improved , Dr Zhang is looking forward to the future, as a new treatment based on each individual's genes, health differences to develop personalized treatment and prevention programs, precision medicine may lead to a new era of medicine Just as DiaCarta's name means, Diacarta says, Diaistic Diagnostic (Diagnosis), Carta's Greek Mappa (Discovery), and DiaCarta's (Diki Biology) will continue to dig deep into the field of diagnostics, making precision medicine truly universal and allowing the general public to benefit from the development of medical technology .